PMID- 27095760
OWN - NLM
STAT- MEDLINE
DCOM- 20170926
LR  - 20181202
IS  - 1007-3418 (Print)
IS  - 1007-3418 (Linking)
VI  - 24
IP  - 3
DP  - 2016 Mar 20
TI  - [Clinical efficacy of pegylated interferon in patients co-infected with HIV and 
      HCV who failed standard interferon therapy].
PG  - 181-5
LID - 10.3760/cma.j.issn.1007-3418.2016.03.005 [doi]
AB  - OBJECTIVE: To investigate the efficacy and safety of pegylated interferon-alpha 
      (PEG-INF-alpha) combined with ribavirin in patients co-infected with human 
      immunodeficiency virus (HIV) and hepatitis C virus (HCV) who failed prior 
      standard interferon therapy. METHODS: A prospective study was performed to 
      analyze HCV RNA load, liver function, and CD4+ count at weeks 0 (baseline), 12, 
      24, and 48 of treatment and at 24 weeks after drug discontinuation in 20 patients 
      co-infected with HIV and HCV who failed standard interferon therapy and were then 
      treated with PEG-INF-alphaand ribavirin. RESULTS: Among the 20 patients, 14 were 
      infected with HCV genotype 1b, 3 with HCV genotype 2a, and 3 failed sequencing. 
      At baseline, the mean CD4(+)count, mean CD8(+)count, and mean CD4(+)/CD8(+)ratio 
      were 406.45 +/- 210.83 cells/ml, 1 076.45 +/- 716.18 cells /ml, and 0.43 +/- 0.17, 
      respectively; the mean HCV RNA load was 6.01 +/- 1.13 log10IU/ml; 12 patients (60%) 
      had abnormal liver function. A total of 14 patients (70%) achieved complete early 
      virologic response, 15 (75%) achieved end-of-treatment virologic response, 7 
      (35%) achieved sustained virologic response (SVR), and 8 (40%) experienced 
      recurrence. The incidence rate of drug-related adverse events during the 
      treatment was 50% (10/20); no serious adverse events occurred, and no patient 
      withdrew from the treatment due to adverse events. At week 48, both CD4(+)and 
      CD8(+)counts of all patients declined significantly compared with the baseline 
      values (P= 0.001 and 0.001), but the CD4(+)/CD8(+)ratio increased significantly 
      (P= 0.032). The SVR group had a significantly lower mean baseline HCV RNA load 
      than the non-SVR group (4.95 +/- 1.18 log10IU/ml vs 6.59 +/- 0.53 log10IU/ml,t= 
      3.49,P= 0.009). CONCLUSION: In the patients co-infected with HIV and HCV who 
      failed standard interferon therapy, PEG-INF-alphacombined with ribavirin has good 
      efficacy and safety, and the patients with a low baseline HCV RNA load are more 
      likely to achieve SVR.
FAU - Ke, Y C
AU  - Ke YC
AD  - Department of Infectious Diseases, Guangzhou No.8 People's Hospital Affiliated to 
      Guangzhou Medical University, Guangzhou 510060, China.
FAU - Li, L H
AU  - Li LH
FAU - Hu, F Y
AU  - Hu FY
FAU - He, Y
AU  - He Y
FAU - Lan, Y
AU  - Lan Y
FAU - Chen, X J
AU  - Chen XJ
FAU - Tang, X P
AU  - Tang XP
FAU - Cai, W P
AU  - Cai WP
LA  - chi
PT  - Journal Article
PL  - China
TA  - Zhonghua Gan Zang Bing Za Zhi
JT  - Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of 
      hepatology
JID - 9710009
RN  - 0 (Anti-Retroviral Agents)
RN  - 0 (Antiviral Agents)
RN  - 0 (Interferon-alpha)
RN  - 0 (RNA, Viral)
RN  - 49717AWG6K (Ribavirin)
SB  - IM
MH  - Anti-Retroviral Agents/therapeutic use
MH  - Antiviral Agents/*therapeutic use
MH  - CD4 Lymphocyte Count
MH  - Coinfection
MH  - Drug Therapy, Combination
MH  - Female
MH  - HIV Infections/*complications/drug therapy/virology
MH  - Hepacivirus/classification/drug effects/isolation & purification
MH  - Hepatitis C, Chronic/complications/*drug therapy/virology
MH  - Humans
MH  - Immunotherapy
MH  - Interferon-alpha/adverse effects/*therapeutic use
MH  - Male
MH  - Prospective Studies
MH  - RNA, Viral/blood
MH  - Recurrence
MH  - Ribavirin/adverse effects/*therapeutic use
MH  - Standard of Care
MH  - Sustained Virologic Response
MH  - Treatment Outcome
MH  - Viral Load
EDAT- 2016/04/21 06:00
MHDA- 2017/09/28 06:00
CRDT- 2016/04/21 06:00
PHST- 2016/04/21 06:00 [entrez]
PHST- 2016/04/21 06:00 [pubmed]
PHST- 2017/09/28 06:00 [medline]
AID - 10.3760/cma.j.issn.1007-3418.2016.03.005 [doi]
PST - ppublish
SO  - Zhonghua Gan Zang Bing Za Zhi. 2016 Mar 20;24(3):181-5. doi: 
      10.3760/cma.j.issn.1007-3418.2016.03.005.